The Advantage of UFT in the Patients with Stage IA & IB Lung Cancer after Complete Resection.
10.5124/jkma.2003.46.1.21
- Author:
Doo Yun LEE
1
Author Information
1. Department of Thoracic Surgery, Yongdong Severance Hospital, Yonsei University College of Medicine, Korea. dylee@yumc.yonsei.ac.kr
- Publication Type:Original Article
- Keywords:
Non-small cell lung cancer;
UFT
- MeSH:
Carcinoma, Non-Small-Cell Lung;
Diagnosis;
Female;
Humans;
Korea;
Lung Neoplasms*;
Lung*;
Lymph Node Excision;
Male;
Recurrence;
Seoul;
Survival Rate
- From:Journal of the Korean Medical Association
2003;46(1):21-28
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Despite complete resection of tumor and mediastinal lymph node dissection, the post-operative survival rate of early stage I non-small cell carcinoma is not so good due to increased recurrences. So, we tried to use one of the chemotherapeutic agents after complete resection of lung carcinoma even though the pathologic final diagnosis is stage IA or IB in order to improve post-operative survivals. One-hundred and eight male and 23 female patients (mean age: 62 years, range: 28~83 years) participated in this clinical study from January 1992 to April 2002 at the Department of Thoracic and Cardiovascular Surgery, Yongdong Severance Hospital, Yonsei University, College of Medicine, Seoul, Korea. Twenty-nine patients were in stage IA and 102 were in stage IB. Among them, 3 patients died from surgical problems and 3 patients died from non surgical problems. Fifty-six patients were placed in the UFT treated group and 61 patients were in the control group. The 5-year survival rate of the patients treated with UFT was 88.6% and the 5-year survival rate of the patients in control group was 72.3% (p=0.0596). The results of our trial indicate that even patients with stage IA and IB non-small cell lung carcinoma would be benefited from orall UFT after complete surgical resection of the tumor.
